Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Post by Dachs1on May 23, 2016 8:28am
213 Views
Post# 24897163

Skin whitening market powers on despite Kanebo lawsuits

Skin whitening market powers on despite Kanebo lawsuitshttps://www.cosmeticsbusiness.com/news/article_page/Skin_whitening_market_powers_on_despite_Kanebo_lawsuits/118316

Skin whitening market powers on despite Kanebo lawsuits

 

 

It’s been a rough few of years for Kanebo in the skin whitening arena as thousands of consumers took the brand to task after suffering skin damage from the inclusion of the brightening ingredient Rhododenol in some of its products.

The subsidiary of Japanese cosmetics giant Kao Group was forced to pull 700,888 products from shelves across the globe after the artificial compound, 4-(4-hydroxyphenyl)-2-butanone, which is normally taken from the bark of the white birch tree, caused vitiligo-like symptoms of blotchy skin and discolouration.

Four years on from the first complaint, Kanebo has now made 15,350 settlement agreements with consumers affected by adverse skin damage, while 19,584 consumers have been confirmed as having vitiligo-like symptoms (as of 13 May). Cosmetics Business caught up with Kanebo to discuss what business in the whitening sector looks like now for the company and what its plans are for securing consumer confidence again.

Bullboard Posts